Daniel Neumann, MD
Gastroenterology · Suffolk, VANPI 1295719094
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.6%. Reporting peaked in 2023 at $3,131 and has fallen 68.7% since, to $980 in 2025.
Across 290 payments — averaging $36.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- AbbVie$2K
- Exact Sciences$1K
- Medtronic$1K
- Roche Diagnostics Corporation$717
- Takeda Pharmaceuticals U.S.A., Inc.$592
- plus $3K from 23 others
Across 36 payments — averaging $7838.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novavax Inc$225K
- GSK$36K
- Pfizer$21K
What the payments were for
- Consulting fees$1,95018%
- Speaking & faculty fees$1,28512%
- Travel & lodging$1,59115%
- Food & beverage$5,88455%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $1,885 |
| AbbVie | 91 | $1,774 |
| Exact Sciences | 2 | $1,416 |
| Medtronic | 16 | $1,152 |
| Roche Diagnostics Corporation | 3 | $717 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $592 |
| Johnson & Johnson | 25 | $578 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $531 |
| Lilly USA, LLC | 10 | $504 |
| Gilead | 6 | $192 |
| Boston Scientific | 3 | $148 |
| Echosens North America, Inc. | 3 | $144 |
| Merck | 9 | $143 |
| Ardelyx, Inc. | 6 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $119 |
| Ironwood Pharmaceuticals, Inc | 7 | $109 |
| Bristol Myers Squibb | 7 | $101 |
| Intercept Pharmaceuticals, Inc. | 6 | $100 |
| Nestle Healthcare Nutrition Inc. | 5 | $93 |
| Braintree Laboratories, Inc. | 6 | $82 |
| Ferring Pharmaceuticals Inc. | 2 | $51 |
| Pfizer | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Romark Laboratories, LC | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Intra-sana Laboratories | 1 | $15 |
| QOL Medical, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cologuard Collection Kit$1,350
- ZEPOSIA$1,285
- GI Genius$821
- iScan Coreo$504
- STELARA$242
- VIRTUOSO System for IHC$213
- OMVOH$125
How this compares
$10,710 in reported general payments places this provider in the 80th percentile of 473 gastroenterology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 25 | $35,522 |
| Dexlansoprazole DrDexlansoprazole | 23 | $8,543 |
| Pantoprazole Sodium | 165 | $2,562 |
| Omeprazole | 105 | $1,632 |
| Sucralfate | 11 | $1,047 |
| Colestipol Hcl | 20 | $990 |
| Esomeprazole Magnesium | 21 | $573 |
| LoperamideLoperamide Hcl | 13 | $507 |
| Dicyclomine Hcl | 43 | $481 |
| Lansoprazole | 27 | $355 |
| Famotidine | 18 | $252 |
| Ondansetron OdtOndansetron | 25 | $182 |
| Metoclopramide Hcl | 18 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,774 | $35,52225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 473 gastroenterology providers in Virginia.
Other gastroenterology in Suffolk
- Larry ClarkLynchburg$1.2M
- Arun SanyalRichmond$855K
- Mitchell ShiffmanNewport News$635K
- Bryan SauerCharlottesville$540K
- Michael RyanNorfolk$335K
- Brian WentworthCharlottesville$276K
- Vanessa ShamiCharlottesville$210K
- Ali SiddiquiFairfax$167K
- Michael FuchsRichmond$126K
- Michael ManetasRichmond$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.